Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy

(2019) Yuan Wei et al.   JOURNAL OF CLINICAL INVESTIGATION

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

(2019) Alexander Haragan et al.   LUNG CANCER

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer

(2018) H Wang et al.   ANNALS OF ONCOLOGY

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations

(2018) Bryce Noll et al.   CANCER CYTOPATHOLOGY

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas

(2018) Eleanor Russell-Goldman et al.   CANCER CYTOPATHOLOGY

Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients

(2018) Marius Ilie et al.   CANCER CYTOPATHOLOGY

Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis

(2018) Fausto Petrelli et al.   Clinical Lung Cancer

PD-L1 immunoexpression in matched biopsy and liquid based cytology samples of advanced stage non-small cell lung carcinomas

(2018) Deepali Jain et al.   CYTOPATHOLOGY

PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion

(2018) Yen-Han Tseng et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

(2018) Ming Sound Tsao et al.   Journal of Thoracic Oncology

The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials

(2018) Binghao Zhao et al.   Cancer Medicine

The Use of Cytologic Material in Melanoma for PD-L1 Immunostaining

(2018) Eva Bashover et al.   CYTOPATHOLOGY

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay

(2018) Enrico Munari et al.   CANCER CYTOPATHOLOGY

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism

(2018) David A. Knorr et al.   CLINICAL CANCER RESEARCH

Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer

(2018) Elisa Capizzi et al.   LUNG CANCER

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

(2018) A. N. Niemeijer et al.   Nature Communications

Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities

(2018) Matthew P. Humphries et al.   Journal of Thoracic Oncology

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability

(2017) Enrico Munari et al.   Oncotarget

Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx

(2017) Birgit G. Skov et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer

(2017) Yunjian Pan et al.   Journal of Thoracic Disease

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

(2016) H. Kadara et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer

(2015) Jianya Zhou et al.   HISTOPATHOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

(2014) K. M. Kerr et al.   ANNALS OF ONCOLOGY

Detection ofALKrearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: A comparison of Ventana immunohistochemistry and fluorescence in situ hybridization

(2014) Weiya Wang et al.   CANCER CYTOPATHOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

(2011) Erik Thunnissen et al.   LUNG CANCER